Cephalon agreed to pay about $590 million to acquire Swiss drugmaker Mepha, allowing it to double its international business and expand into Europe and two other markets. The acquisition is expected to conclude in 10 to 12 weeks and could enable the biotech firm to tap into branded generics and two other types of pharmaceutical markets.

Related Summaries